Ribozyme Pharmaceuticals

Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

[Read More]